Article Information
History
- December 21, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Natacha Madelon, PhDa,*,
- Nelli Heikkilä, PhDa,*,
- Irène Sabater Royo, MSca,
- Paola Fontannaza,
- Gautier Breville, MDb,
- Kim Lauper, MDc,
- Rachel Goldstein, MSca,
- Alba Grifoni, PhDd,
- Alessandro Sette, PhDd,e,
- Claire-Anne Siegrist, MDa,f,
- Axel Finckh, MDc,
- Patrice H. Lalive, MDb,
- Arnaud M. Didierlaurent, MDa,# and
- Christiane S. Eberhardt, MDa,f,g,#
- aCenter for Vaccinology, Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- bDepartment of Neurosciences, Division of Neurology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
- cDepartment of Medicine, Division of Rheumatology, University Hospital of Geneva & Faculty of Medicine, University of Geneva, Geneva, Switzerland
- dCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, University of California, San Diego, La Jolla, USA
- eDepartment of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, USA
- fDivision of General Pediatrics, Department of Woman, Child and Adolescent Medicine, Faculty of Medicine, University of Geneva; and Center for Vaccinology, Geneva University Hospitals, Geneva, Switzerland
- gEmory Vaccine Center, Emory University School of Medicine, Atlanta, USA
- ↵#Co-corresponding authors Corresponding author: Christiane S. Eberhardt (Christiane.Eberhardt{at}unige.ch), alternate corresponding author: Arnaud Didierlaurent (Arnaud.didierlaurent{at}unige.ch) both: Centre Médical Universitaire, rue Michel-Servet 1, 1211 Genève 4, Switzerland, Phone: +41 22 379 57 77
↵* Natacha Madelon and Nelli Heikkilä contributed equally to this manuscript.
Posted December 21, 2021.
Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients
